Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.

[1]  O. Kiselev,et al.  Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors. , 2013, Current pharmaceutical design.

[2]  N. Ravin,et al.  A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles. , 2013, Virology.

[3]  H. Bo,et al.  Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin. , 2012, Vaccine.

[4]  A. Jegerlehner,et al.  Universal vaccine against influenza virus: Linking TLR signaling to anti‐viral protection , 2012, European journal of immunology.

[5]  N. Ravin,et al.  Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein , 2012, Biochemistry (Moscow).

[6]  Y. Sung,et al.  Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e. , 2011, Vaccine.

[7]  T. Tumpey,et al.  Characterization of the murine Th2 response to immunization with liposomal M2e influenza vaccine. , 2011, Vaccine.

[8]  W. Fiers,et al.  Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection , 2011, The Journal of Immunology.

[9]  F. Kostolanský,et al.  Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein. , 2011, Acta virologica.

[10]  G. Boivin,et al.  Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. , 2008, Vaccine.

[11]  R. K. Evans,et al.  Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. , 2008, Vaccine.

[12]  K. Schwarz,et al.  Efficient induction of mucosal and systemic immune responses by virus‐like particles administered intranasally: implications for vaccine design , 2008, European journal of immunology.

[13]  L. Otvos,et al.  Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse , 2007, Virology Journal.

[14]  T. Tumpey,et al.  Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1 , 2007, Emerging infectious diseases.

[15]  Y. Huang,et al.  Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. , 2007, Vaccine.

[16]  W. Fiers,et al.  Universal influenza A vaccine: optimization of M2-based constructs. , 2005, Virology.

[17]  Ying-hua Chen,et al.  The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. , 2005, International immunopharmacology.

[18]  J. Shiver,et al.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. , 2004, Vaccine.

[19]  W. Fiers,et al.  A "universal" human influenza A vaccine. , 2004, Virus research.

[20]  L. Otvos,et al.  Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. , 2003, Vaccine.

[21]  J. Wood.  Developing vaccines against pandemic influenza. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[22]  G. Leroux-Roels,et al.  Hepatitis B Virus Core Antigen Binds and Activates Naive Human B Cells In Vivo: Studies with a Human PBL-NOD/SCID Mouse Model , 2001, Journal of Virology.

[23]  Walter Fiers,et al.  A universal influenza A vaccine based on the extracellular domain of the M2 protein , 1999, Nature Medicine.

[24]  K. Mozdzanowska,et al.  Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. , 1999, Virology.

[25]  D. Krüger,et al.  Core particles of hepatitis B virus as carrier for foreign epitopes. , 1998, Advances in virus research.

[26]  R. Zinkernagel,et al.  The influence of antigen organization on B cell responsiveness. , 1993, Science.

[27]  Lawrence H. Pinto,et al.  Influenza virus M2 protein has ion channel activity , 1992, Cell.

[28]  R. Lamb,et al.  Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions , 1988, Journal of virology.

[29]  D. Milich,et al.  The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. , 1986, Science.

[30]  R. Lamb,et al.  Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface , 1985, Cell.

[31]  I. V. Antonova,et al.  The Hong Kong influenza virus epidemic in the USSR. , 1969, Bulletin of the World Health Organization.